foscarnet has been researched along with Kidney Diseases in 13 studies
Foscarnet: An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpesviruses and HIV.
phosphonoformic acid : Phosphoric acid in which one of the hydroxy groups is replaced by a carboxylic acid group. It is used as the trisodium salt as an antiviral agent in the treatment of cytomegalovirus retinitis (CMV retinitis, an inflamation of the retina that can lead to blindness) and as an alternative to ganciclovir for AIDS patients who require concurrent antiretroviral therapy but are unable to tolerate ganciclovir due to haematological toxicity.
Kidney Diseases: Pathological processes of the KIDNEY or its component tissues.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Intravenous foscarnet was given on an emergency basis to 30 immunosuppressed patients with cytomegalovirus (CMV) disease, of whom 28 were organ transplant recipients." | 9.06 | Sensitivity of cytomegalovirus to intravenous foscarnet treatment. ( Akesson-Johansson, A; Lernestedt, JO; Lönnqvist, B; Ringdén, O; Wahren, B, 1986) |
| "We present the case of a lung transplant recipient with disseminated crystal precipitation, and granulomatous and fibrinous inflammation after therapy with foscarnet (Foscavir; AstraZeneca, Zug, Switzerland) for recurring ganciclovir-resistant cytomegalovirus (CMV) reactivation." | 7.78 | Crystal precipitation and granulomatous inflammation in multiple organs after foscarnet therapy in a lung transplant recipient. ( Boehler, A; Gaspert, A; Schuurmans, MM; Tischler, V, 2012) |
| "Intravenous foscarnet was given on an emergency basis to 30 immunosuppressed patients with cytomegalovirus (CMV) disease, of whom 28 were organ transplant recipients." | 5.06 | Sensitivity of cytomegalovirus to intravenous foscarnet treatment. ( Akesson-Johansson, A; Lernestedt, JO; Lönnqvist, B; Ringdén, O; Wahren, B, 1986) |
| "We present the case of a lung transplant recipient with disseminated crystal precipitation, and granulomatous and fibrinous inflammation after therapy with foscarnet (Foscavir; AstraZeneca, Zug, Switzerland) for recurring ganciclovir-resistant cytomegalovirus (CMV) reactivation." | 3.78 | Crystal precipitation and granulomatous inflammation in multiple organs after foscarnet therapy in a lung transplant recipient. ( Boehler, A; Gaspert, A; Schuurmans, MM; Tischler, V, 2012) |
| " Although prompt treatment with foscarnet stabilized encephalitis and there were no serious neurological sequelae, the patient developed both hyponatremia and natriuresis 11 days after intravenous administration of foscarnet." | 3.74 | [Salt-wasting nephropathy induced by foscarnet treatment for HHV-6 encephalitis in a hematopoietic stem cell transplant]. ( Akiyama, H; Ando, M; Koshida, A; Najima, Y; Ohashi, K; Sakamaki, H; Yamashita, T, 2008) |
| "Foscarnet is an antiviral agent commonly used for managing patients with cytomegalovirus infection." | 1.30 | Effect of renal disease and hemodialysis on foscarnet pharmacokinetics and dosing recommendations. ( Aweeka, FT; Gambertoglio, JG; Hedman, A; Jacobson, MA; Martin-Munley, S; Omachi, R; Schoenfeld, P; Tsunoda, S, 1999) |
| "Foscarnet is an antiviral agent used to treat cytomegalovirus infection in AIDS patients and in transplant recipients." | 1.30 | Irreversible glomerular lesions induced by crystal precipitation in a renal transplant after foscarnet therapy for cytomegalovirus infection. ( Assem, M; Justrabo, E; Martin, L; Maurice-Estepa, L; Mousson, C; Rifle, G; Tanter, Y; Zanetta, G, 1999) |
| "Foscarnet is an antiviral agent used for the treatment of cytomegalovirus retinitis and acyclovir-resistant herpes simplex virus infections in AIDS patients." | 1.29 | Use of human renal proximal tubule cell cultures for studying foscarnet-induced nephrotoxicity in vitro. ( Cui, X; Drusano, GL; Trifillis, AL, 1993) |
| " Surprisingly, AZT significantly increased serum creatinine levels on Days 5 and 11 of treatment (up to 40% increase), whereas PFA was less toxic (only approximately 17% increase on Day 5 of treatment)." | 1.29 | In vivo toxicity of foscarnet and zidovudine given alone or in combination. ( Beauchamp, D; Bergeron, MG; Désormeaux, A; Gourde, P; Omar, RF; Tremblay, M, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (7.69) | 18.7374 |
| 1990's | 8 (61.54) | 18.2507 |
| 2000's | 3 (23.08) | 29.6817 |
| 2010's | 1 (7.69) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Miyamoto, K | 1 |
| Segawa, H | 1 |
| Ito, M | 1 |
| Kuwahata, M | 1 |
| Tischler, V | 1 |
| Schuurmans, MM | 1 |
| Boehler, A | 1 |
| Gaspert, A | 1 |
| Sakamoto, M | 1 |
| Najima, Y | 1 |
| Ohashi, K | 1 |
| Ando, M | 1 |
| Koshida, A | 1 |
| Yamashita, T | 1 |
| Akiyama, H | 1 |
| Sakamaki, H | 1 |
| Trifillis, AL | 1 |
| Cui, X | 1 |
| Drusano, GL | 1 |
| Omar, RF | 1 |
| Gourde, P | 1 |
| Désormeaux, A | 1 |
| Tremblay, M | 1 |
| Beauchamp, D | 1 |
| Bergeron, MG | 1 |
| Brooks, DP | 1 |
| Ali, SM | 1 |
| Contino, LC | 1 |
| Stack, E | 1 |
| Fredrickson, TA | 1 |
| Feild, J | 1 |
| Edwards, RM | 1 |
| Aweeka, FT | 1 |
| Jacobson, MA | 2 |
| Martin-Munley, S | 1 |
| Hedman, A | 1 |
| Schoenfeld, P | 1 |
| Omachi, R | 1 |
| Tsunoda, S | 1 |
| Gambertoglio, JG | 1 |
| Justrabo, E | 1 |
| Zanetta, G | 1 |
| Martin, L | 1 |
| Assem, M | 1 |
| Mousson, C | 1 |
| Maurice-Estepa, L | 1 |
| Rifle, G | 1 |
| Tanter, Y | 1 |
| Farese, RV | 1 |
| Schambelan, M | 1 |
| Hollander, H | 1 |
| Stringari, S | 1 |
| Deray, G | 1 |
| Katlama, C | 1 |
| Dohin, E | 1 |
| Akesson-Johansson, A | 1 |
| Lernestedt, JO | 1 |
| Ringdén, O | 1 |
| Lönnqvist, B | 1 |
| Wahren, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Dose-Ranging, Open-Labelled Trial of Foscarnet Salvage Therapy for AIDS Patients With Sight-Threatening CMV Retinitis Who Cannot Be Treated With Ganciclovir Due To Myelosuppression or Treatment Failure[NCT00000691] | Phase 2 | 156 participants | Interventional | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for foscarnet and Kidney Diseases
| Article | Year |
|---|---|
[Progress in the identification of intestinal Pi transport inhibitors].
Topics: Animals; Antiviral Agents; Chronic Disease; Drug Design; Foscarnet; Humans; Hyperphosphatemia; Kidne | 2009 |
[Adverse effects and safety of antimicrobial agents--nephrotoxicity].
Topics: Amphotericin B; Anti-Bacterial Agents; Antifungal Agents; Antiviral Agents; Foscarnet; Humans; Kidne | 2007 |
1 trial available for foscarnet and Kidney Diseases
| Article | Year |
|---|---|
Sensitivity of cytomegalovirus to intravenous foscarnet treatment.
Topics: Antiviral Agents; Bone Marrow Transplantation; Cytomegalovirus; Cytomegalovirus Infections; Female; | 1986 |
10 other studies available for foscarnet and Kidney Diseases
| Article | Year |
|---|---|
Crystal precipitation and granulomatous inflammation in multiple organs after foscarnet therapy in a lung transplant recipient.
Topics: Adult; Antiviral Agents; Crystallization; Cytomegalovirus Infections; Foscarnet; Granuloma; Heart Di | 2012 |
[Salt-wasting nephropathy induced by foscarnet treatment for HHV-6 encephalitis in a hematopoietic stem cell transplant].
Topics: Antiviral Agents; Encephalitis, Viral; Female; Foscarnet; Hematopoietic Stem Cell Transplantation; H | 2008 |
Use of human renal proximal tubule cell cultures for studying foscarnet-induced nephrotoxicity in vitro.
Topics: Adolescent; Adult; Cells, Cultured; Foscarnet; Humans; Kidney Diseases; Kidney Tubules, Proximal; Ma | 1993 |
In vivo toxicity of foscarnet and zidovudine given alone or in combination.
Topics: Animals; Antiviral Agents; Female; Foscarnet; Hematologic Diseases; Injections, Intraperitoneal; Kid | 1996 |
Phosphate excretion and phosphate transporter messenger RNA in uremic rats treated with phosphonoformic acid.
Topics: Animals; Carrier Proteins; Disease Models, Animal; Foscarnet; Kidney Diseases; Male; Nephrectomy; Ph | 1997 |
Drugs for non-HIV viral infections.
Topics: 2-Aminopurine; Abnormalities, Drug-Induced; Acyclovir; Amantadine; Antiviral Agents; Cidofovir; Cont | 1997 |
Effect of renal disease and hemodialysis on foscarnet pharmacokinetics and dosing recommendations.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Female; Foscarnet; Health Planning Guidelines; Humans | 1999 |
Irreversible glomerular lesions induced by crystal precipitation in a renal transplant after foscarnet therapy for cytomegalovirus infection.
Topics: Biopsy; Birefringence; Crystallization; Cytomegalovirus Infections; Foscarnet; Humans; Kidney Diseas | 1999 |
Nephrogenic diabetes insipidus associated with foscarnet treatment of cytomegalovirus retinitis.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Diabetes In | 1990 |
Prevention of foscarnet nephrotoxicity.
Topics: Adult; Antiviral Agents; Cytomegalovirus Infections; Eye Infections, Viral; Female; Fluid Therapy; F | 1990 |